S J Hadziyannis

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 352:2673-81. 2005
  2. ncbi Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
    Irene Rapti
    Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens, Greece
    Hepatology 45:307-13. 2007
  3. ncbi Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, National and Kapodistrian University of Athens, Athens, Greece
    Gastroenterology 143:629-36.e1. 2012
  4. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  5. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Gastroenterology 131:1743-51. 2006
  6. ncbi Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 348:800-7. 2003
  7. ncbi Treatment of HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Semin Liver Dis 23:81-8. 2003
  8. ncbi Peginterferon-alpha2a (40 kDa) for chronic hepatitis C
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Ave, 11526 Athens, Greece
    Expert Opin Pharmacother 4:541-51. 2003
  9. ncbi New developments in the treatment of chronic hepatitis B
    Stephanos J Hadziyannis
    Athens University, Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Ave, 11526 Athens, Greece
    Expert Opin Biol Ther 6:913-21. 2006
  10. ncbi Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 11526 Athens, Greece
    Expert Rev Anti Infect Ther 2:475-83. 2004

Collaborators

Detail Information

Publications56

  1. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 352:2673-81. 2005
    ..We evaluated the effect of continued therapy as compared with cessation of therapy...
  2. ncbi Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
    Irene Rapti
    Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens, Greece
    Hepatology 45:307-13. 2007
    ....
  3. ncbi Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, National and Kapodistrian University of Athens, Athens, Greece
    Gastroenterology 143:629-36.e1. 2012
    ..Little is known about the biochemical and virological effects of stopping long-term nucleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB)...
  4. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  5. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Gastroenterology 131:1743-51. 2006
    ..We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for up to 240 weeks...
  6. ncbi Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 348:800-7. 2003
    ..Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials...
  7. ncbi Treatment of HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Semin Liver Dis 23:81-8. 2003
    ..Many other antiviral agents and immunomodulatory approaches are currently evaluated for CHB, but, besides IFN-alpha, none has yet been convincingly shown to induce sustained off-therapy responses...
  8. ncbi Peginterferon-alpha2a (40 kDa) for chronic hepatitis C
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Ave, 11526 Athens, Greece
    Expert Opin Pharmacother 4:541-51. 2003
    ..PEG-IFN-alpha(2a) (40 kDa) is expected to improve the efficacy and tolerability of treatment for chronic hepatitis C...
  9. ncbi New developments in the treatment of chronic hepatitis B
    Stephanos J Hadziyannis
    Athens University, Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Ave, 11526 Athens, Greece
    Expert Opin Biol Ther 6:913-21. 2006
    ....
  10. ncbi Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 11526 Athens, Greece
    Expert Rev Anti Infect Ther 2:475-83. 2004
    ..All these characteristics make adefovir dipivoxil an important drug for the treatment of hepatitis B virus infection and an excellent candidate for long-term maintenance therapy in chronic viral B liver disease...
  11. ncbi Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others)
    Stephanos J Hadziyannis
    Department of Medinine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, Athens, Greece
    J Hepatol 39:S172-6. 2003
  12. ncbi Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study
    S Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 7:235-40. 2000
    ..Further studies are warranted to evaluate the efficacy of prolonged combination schemes with nucleoside analogues and IFN, compared to IFN monotherapy...
  13. ncbi Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients
    Stephanos J Hadziyannis
    Henry Dunant Hospital, Department of Medicine and Hepatology, Athens, Greece
    Expert Opin Investig Drugs 16:777-86. 2007
    ..There are no treatment paradigms as yet of combination therapy from the very outset with two nucleoside analogues for use in treatment-naive patients...
  14. ncbi Emerging treatments in chronic hepatitis B
    Stephanos J Hadziyannis
    Henry Dunant Hospital, Department of Medicine and Hepatology, 107 Messogion Avenue, Athens 11526, Greece
    Expert Opin Emerg Drugs 9:207-21. 2004
    ..Long-term maintenance treatment with antiviral agent(s) with good safety and tolerability profiles and low resistance rates appears to be the most realistic future therapeutic option for most chronic hepatitis B patients...
  15. ncbi Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection
    S J Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, 114 Vas Sophias Avenue, 115 27 Athens, Greece
    Antiviral Res 52:91-8. 2001
    ..e. chronic hepatitis are outlined...
  16. ncbi Natural history of chronic hepatitis B in Euro-Mediterranean and African countries
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    J Hepatol 55:183-91. 2011
    ....
  17. ncbi Telbivudine in the treatment of chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 115 26 Athens, Greece
    Expert Rev Gastroenterol Hepatol 2:13-22. 2008
    ..The results are critically presented and the evolving concept of effective long-term telbivudine and other nucleos(t)ide analog therapy, predicted by the extent of suppression of HBV replication at week 24, are analyzed and discussed...
  18. ncbi Milestones and perspectives in viral hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital and Liver Research Unit, Athens University, Evgenidion Hospital, Athens, Greece
    Liver Int 31:129-34. 2011
    ..However for the moment, realistic efforts should be made to make treatment as widely available and affordable as possible and to apply current therapies to significantly reduce HBV morbidity and mortality...
  19. ncbi Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
    S J Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Hepatology 32:847-51. 2000
    ..However, response rates tend to decrease with time and breakthroughs due to YMDD mutants accumulate. ALT activity during breakthroughs often exceeds the baseline and may reach even acute hepatitis levels...
  20. ncbi A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B
    E K Manesis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 23:99-106. 2006
    ..However, a 12-month interferon monotherapy course may achieve similar responses...
  21. ncbi Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit
    A S Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 15:551-7. 2001
    ....
  22. ncbi Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels
    Emanuel K Manesis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Antivir Ther 12:73-82. 2007
    ..Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment...
  23. ncbi The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Hepatol 34:306-13. 2001
    ..Therefore, long-term biochemical remission appears to represent a satisfactory therapeutic target in this setting...
  24. ncbi Old and emerging therapies in chronic hepatitis C: an update
    M Deutsch
    Academic Department of Internal Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 15:2-11. 2008
    ....
  25. ncbi Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
    George V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Hepatology 36:219-26. 2002
    ..ALT activity peaks close to the onset of biochemical breakthrough, decreasing thereafter but remaining persistently abnormal with fluctuating levels...
  26. ncbi Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis
    G V Papatheodoridis
    Hippokration General Hospital, Athens, Greece
    Gut 52:404-9. 2003
    ....
  27. ncbi Diagnosis and management of pre-core mutant chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 8:311-21. 2001
    ..Several other antiviral agents are currently being evaluated in this setting with combined regimens being the most reasonable step for the near future...
  28. ncbi Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B
    E K Manesis
    Academic Department of Medicine, Hippokration General Hospital, 114 Vas Sophias Avenue, Athens 115 25, Greece
    Gastroenterology 121:101-9. 2001
    ..CONCLUSIONS: IFN induced long-term biochemical and virologic remission in approximately 18% of naive or retreated patients with CHBe-. Sustained responders exhibited significant histologic improvement and a high rate of HBsAg loss...
  29. ncbi Why and how to treat chronic hepatitis C
    S J Hadziyannis
    Academic Department of Medicine, Hippokration General Hospital, Athens
    Can J Gastroenterol 14:45B-48B. 2000
    ..IFN alpha therapy may also prove to be effective in reducing the rate of HCC development in CHC regardless of whether a virological response is achieved, but this remains to be established...
  30. ncbi Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece
    S P Savvas
    Second Department of Medicine, Athens University, Athens, Greece
    J Viral Hepat 12:551-7. 2005
    ..The presence of cirrhosis was associated only with the duration of infection. These observations have impact both on prevention and treatment...
  31. ncbi Review article: current management of chronic hepatitis B
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 19:25-37. 2004
    ..Adefovir is also effective against lamivudine-resistant strains. Many other anti-viral agents, immunomodulatory approaches and combination therapies are currently being evaluated in chronic hepatitis B...
  32. ncbi Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis
    G V Papatheodoridis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Aliment Pharmacol Ther 15:689-98. 2001
    ..Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non-sustained responders...
  33. ncbi Deep jaundice in an adolescent
    M Deutsch
    B Academic Department of Internal Medicine, Athens, Greece
    Postgrad Med J 79:544, 548-9. 2003
  34. ncbi Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients
    Andreas Laras
    Hepatitis Research Laboratory, Athens University School of Medicine, and Henry Dunant Hospital, Athens, Greece
    Hepatology 44:694-702. 2006
    ..The combined measurement of cccDNA and pgRNA levels provides valuable information on the presence and replicative activity of intrahepatic HBV cccDNA...
  35. ncbi Nonalcoholic fatty liver disease: from clinical recognition to treatment
    Vassilios A Sevastianos
    Department of Medicine and Hepatology, Henry Dunant Hospital, 107 Messogion Avenue, 11526 Athens, Greece
    Expert Rev Gastroenterol Hepatol 2:59-79. 2008
    ..Physical exercise and a low calorie diet in combination with the gradual loss of body weight represent the cornerstone for the management of NAFLD patients...
  36. ncbi Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B
    D Vassilopoulos
    Academic Department of Medicine, Athens University School of Medicine, Hippokration General Hospital, Athens, Greece
    J Viral Hepat 15:817-26. 2008
    ....
  37. ncbi Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection
    Emanuel K Manesis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Am J Gastroenterol 98:2261-7. 2003
    ....
  38. ncbi Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Semin Liver Dis 26:130-41. 2006
    ..Combination therapy with adefovir added to LMV in LMV-resistant patients is extremely effective; cases of adefovir-resistance have not been reported to date...
  39. ncbi In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter
    Andreas Laras
    Second Department of Medicine, Athens University School of Medicine, Athens, Greece
    Virology 295:86-96. 2002
    ..Our in vivo study shows therefore that the double A1762T/G1764A mutation is associated with the specific suppression of precore mRNA synthesis directed by the HBV core promoter...
  40. ncbi Autoimmune hepatitis associated with the antiphospholipid syndrome
    S P Dourakis
    Academic Department of Medicine, Hippokration General Hospital, Athens, Greece
    Eur J Gastroenterol Hepatol 13:591-3. 2001
    ..In conclusion, secondary antiphospholipid syndrome may accompany autoimmune hepatitis...
  41. ncbi High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma
    G Dalagiorgou
    Molecular Virology Laboratory, Hellenic Pasteur Institute, Athens, Greece
    J Gen Virol 92:1343-51. 2011
    ..No core+1-specific reactivity was detected in any of the control samples. In conclusion, the high occurrence of anti-core+1 antibodies in the serum of HCC patients suggests a role for the ARFP/F/core+1 protein in the pathogenesis of HCC...
  42. ncbi Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis
    Melanie Deutsch
    Academic Department of Internal Medicine Hippocration General Hospital, Athens, Greece
    Eur J Gastroenterol Hepatol 20:5-9. 2008
    ..In contrast, extrahepatic malignancies have been reported to be significantly associated with PBC. The aim of this study was to determine the incidence of HCC and of extrahepatic malignancies in a large cohort of patients with PBC...
  43. ncbi Precore mutant chronic hepatitis B - approach to management
    Stephanos J Hadziyannis
    Department of Medicine Hepatology, Henry Dunant Hospital, Athens, Greece
    MedGenMed 5:1. 2003
  44. ncbi Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs
    George V Papatheodoridis
    Academic Department of Medicine, Henry Dunant Hospital, Athens, Greece
    Am J Med 116:601-5. 2004
    ..7; 95% confidence interval: 1.2 to 2.5; P = 0.004). CONCLUSION: H. pylori infection almost doubles the risk of upper gastrointestinal bleeding among users of NSAIDs...
  45. ncbi Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Nancy Reau
    Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Am J Gastroenterol 103:1981-8. 2008
    ..The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4...
  46. ncbi Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin
    Eric Snoeck
    Exprimo NV, Mechelen, Belgium
    Liver Int 28:61-71. 2008
    ..Currently, the approved dosage of ribavirin has not been studied in patients with 'normal' alanine aminotransferase (ALT) levels...
  47. ncbi Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy
    Stephanos J Hadziyannis
    J Hepatol 36:280-2. 2002
  48. ncbi Treatment of chronic hepatitis C infection with peginterferons plus ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
    Semin Liver Dis 24:47-54. 2004
    ..This article reviews the data from clinical trials of peginterferon alfa-2a and peginterferon alfa-2b...
  49. ncbi Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine
    George V Papatheodoridis
    2nd Academic Department of Internal Medicine, Hippokration General Hospital of Athens, Greece
    Hepatology 42:121-9. 2005
    ..In such patients with advanced fibrosis, close follow-up for lamivudine resistance and prompt onset of additional antiviral therapy is required or the ab initio use of agent(s) with low resistance rates should be considered...
  50. ncbi A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    Gastroenterology 129:1198-209. 2005
    ..This randomized, dose-ranging, phase 2 study compared the efficacy and safety of entecavir with lamivudine in lamivudine-refractory patients...
  51. ncbi Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  52. ncbi Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  53. ncbi Treatment options for chronic hepatitis B not responding to interferon
    Stephanos J Hadziyannis
    J Hepatol 38:853-5. 2003
  54. ncbi Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, Paris, France
    Kidney Int 66:1153-8. 2004
    ..We report a complete analysis on the renal tolerance of ADV at the currently approved dose of 10 mg daily for the treatment of chronic hepatitis B...
  55. ncbi Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
    ..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
  56. ncbi Serum HBV-DNA levels in inactive hepatitis B virus carriers
    Emanuel K Manesis
    Gastroenterology 122:2092-3; author reply 2093. 2002